Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2023 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
March 01, 2023 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
February 01, 2023 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
January 04, 2023 16:05 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
January 03, 2023 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
December 10, 2022 15:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reportingThe ORR of 89% and CR rate of 43% for patients with...
December 01, 2022 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
November 14, 2022 17:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
November 03, 2022 16:01 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

Initiated Phase 3 global registrational Study ZILO-301 of our zilovertamab product candidate targeting ROR1 in combination with ibrutinib for the treatment of patients with MCLReceived acceptance for...
November 03, 2022 09:05 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...